Teva Pharmaceutical Indus Affirms FY2026 Adj EPS Guidance of $2.57-$2.77 vs $2.67 Est; Affirms FY2026 Sales Guidance of $16.400B-$16.800B vs $16.570B Est

Benzinga Newsdesk www.benzinga.com Negative 51.2%

Neg 51.2% Neu 0% Pos 0%

Teva Pharmaceutical Indus (NYSE:TEVA) affirms FY2026 Adj EPS guidance from $2.57-$2.77 to $2.57-$2.77 vs $2.67 analyst estimate. Affirms FY2026 sales outlook from $16.400 billion-$16.800 billion to $16.400 billion-$16.800 billion vs $16.570 billion estimate.